DNAfusion

DNAfusion detects EML4-ALK gene fusions in liquid biopsy NGS data to improve sensitivity of fusion detection for molecular profiling and monitoring of stage IV non-small cell lung cancer (NSCLC).

Key Features:

• Increased Sensitivity: In a training cohort of 48 blood samples (41 EML4-ALK-positive stage IV NSCLC and 7 healthy controls) DNAfusion achieved 61.0% sensitivity versus 36.6% for AVENIO.
• Validation and Verification: In a blinded validation cohort of 24 EML4-ALK-positive and 24 EML4-ALK-negative stage IV NSCLC patients DNAfusion sensitivity was 62.5% versus 29.2% for AVENIO, and newly identified positives were confirmed by droplet digital PCR.
• High Specificity: DNAfusion exhibited 100% specificity in both the training and validation cohorts.
• NGS BAM compatibility: Processes BAM files generated by commercially available NGS platforms such as AVENIO for fusion detection within the R/Bioconductor framework.

Scientific Applications:

• NSCLC tumor monitoring: Detects EML4-ALK fusions in liquid biopsies to monitor tumor dynamics in stage IV NSCLC.
• Patient stratification: Identifies EML4-ALK-positive patients to inform selection and monitoring of ALK-targeted therapies.
• Oncogenic driver research: Enables detection of EML4-ALK fusion events from circulating tumor DNA for studies of cancer progression and treatment response.

Methodology:

Processes BAM files from NGS data (e.g., AVENIO) within the R/Bioconductor framework using advanced bioinformatics algorithms to identify EML4-ALK gene fusions.